Company Description
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.
Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer.
The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.
The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute.
Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Geordan Pursglove |
Contact Details
Address: 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 United States | |
| Phone | 631 830 7092 |
| Website | lixte.com |
Stock Details
| Ticker Symbol | LIXTW |
| Exchange | NASDAQ |
| Stock Type | Warrants |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001335105 |
| CUSIP Number | 539319111 |
| ISIN Number | US5393191110 |
Key Executives
| Name | Position |
|---|---|
| Geordan G. Pursglove | Chief Executive Officer and Chairman |
| Bastiaan van der Baan M.Sc. | President, Chief Scientific Officer and Director |
| Robert Neal Weingarten | Chief Financial Officer, Vice President and Secretary |
| Johannes Henricus Matthias Schellens M.D., Ph.D. | Consultant and Chief Medical Officer |